Cancer Gene Theory Challenged

November 06, 1996

BUFFALO, NY - Researchers at Roswell Park Cancer Institute have cast doubt on the widely held belief that the mutation of the p53 gene triggers the chain reaction of cancer development.

"At least not for colorectal cancer," said Garth Anderson, PhD, a senior scientist who studied gene mutations in this disease with colleagues at the Institute. "Clearly, p53 mutation plays an important role in cancer development, but it does not appear to initiate the multi-step process."

The results of this study are highlighted in the November 6 issue of the Journal of the National Cancer Institute.

This research breaks faith with dogma long held by the scientific community regarding the role of the p53 gene and cancer tumors.

"We can compare our investigation to another - the explosion aboard TWA flight 800 which most experts initially believed was caused by a bomb," remarked Dr. Anderson. "The evidence just wasn't there to support that conclusion, prompting a return trip to the drawing board, or in our case, the laboratory."

It has long been thought that mutations in the p53 gene caused the gene system to crash, creating a state called genomic instability. Looking at actual colorectal tumors and their genomic instability, the Roswell Park researchers discovered that patients with rapidly evolving tumors had not lost the p53 gene function. p53 serves a regulatory function by binding DNA, in turn controlling how cells grow and divide.

A series of mutations must occur before a normal cell becomes cancerous. Conventional wisdom said p53 played the central role when gene systems ran amok. That is simply not the case, Anderson says.

"This research is pretty clear. p53 is the last step, not the first," explained the scientist. "There is something else occurring - a mysterious enigma which controls cells and causes them to progress to a cancerous state. If we can find this enigma and shut down this process of instability, we can shut down the cancer process."

Such research also may lead scientists to determine how to make cancer cells less resistant to potentially effective chemotherapies.

"The key question becomes, if not p53, then what?" asks Morton S. Kahlenberg, MD of the Division of Surgical Oncology at Roswell Park and a key member of the research team. "We are now focusing on identifying what actually is or are the driving factors behind the predominant form of genomic instability seen in cancer; once found, these should become invaluable new therapeutic targets and important new diagnostic tools."

Roswell Park, founded in 1898, is the world's first cancer research and treatment center.

Roswell Park Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to